Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant VEGFA anticorps

Cet anticorps Humanized Monoclonal détecte spécifiquement VEGFA dans WB, ELISA et FACS. Il présente une réactivité avec des échantillons de Humain.
Rockland
N° du produit ABIN7540553
N° du produit (Fournisseur): 400-001-mt4
645,72 €
Frais d'envoi 40,00 €, glace carbonique 20,00 € et TVA exclus
50 μg
Destination: France
Envoi sous 5 à 8 jours ouvrables

Aperçu rapide pour Recombinant VEGFA anticorps (ABIN7540553)

Antigène

Voir toutes VEGFA Anticorps
VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

Type d'anticorp

Recombinant Antibody

Fragment

Fab fragment

Reactivité

  • 193
  • 115
  • 85
  • 24
  • 23
  • 19
  • 19
  • 8
  • 6
  • 6
  • 5
  • 5
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
Humain

Hôte

  • 198
  • 82
  • 15
  • 12
  • 2
  • 1
  • 1
Humanized

Clonalité

  • 202
  • 105
  • 2
Monoclonal

Conjugué

  • 167
  • 42
  • 22
  • 10
  • 6
  • 6
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp VEGFA est non-conjugé

Application

  • 211
  • 94
  • 79
  • 40
  • 40
  • 38
  • 37
  • 30
  • 25
  • 16
  • 16
  • 10
  • 10
  • 9
  • 9
  • 8
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Clone

Lucentis
  • N° du produit (Fournisseur)

    400-001-mt4

    Fournisseur

    Rockland

    Fonction

    Recombinant Anti-VEGF Fab Antibody

    Purification

    Humanized Recombinant VEGF-A Fab fragment was expressed in CHO cells.

    Pureté

    > 95 % by SDS-PAGE analysis

    Stérilité

    Sterile filtered

    Isotype

    IgG1
  • Indications d'application

    ELISA_Dilution: User Optimized

    Flow_Cytometry_Dilution: User Optimized

    Western_Blot_Dilution: User Optimized

    Commentaires

    Humanized Recombinant Anti-VEGFA Fab fragment Antibody has been tested for use in Flow Cytometry, Western Blot, and ELISA. This antibody recognizes structured VEGF-A and will work in western blot when the protein has not been denatured with DTT or bMe. Although not tested, this antibody could be useful in in IHC and in in-vivo and other cellular assays. Specific conditions for reactivity should be optimized by the end user.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

    Stabilizer: 30 % Glycerol

    Preservative: None

    Agent conservateur

    Without preservative

    Stock

    -20 °C

    Stockage commentaire

    Store vial at -20° C. Dilute only prior to immediate use.

    Date de péremption

    6 months
  • Antigène

    VEGFA (Vascular Endothelial Growth Factor A (VEGFA))

    Autre désignation

    VEGF-A

    Sujet

    Anti-VEGF-A Antibody, Ranibizumab, Lucentis, Fab fragment of Bevacizumab or Avastin, Vascular endothelial growth factor A, VEGF A, VEGFA, Vascular permeability factor, VPF,VEGF is a potent mitogen in embryonic and somatic angiogenesis with specificity for vascular endothelial cells. VEGF forms homodimers and exists in four different isoforms. Overall, the VEGF monomer resembles that of PDGF, but its N-terminal segment is helical rather than extended. VEGF shares homologies of about 21 % and 24 % respectively with the A and B chains of human platelet-derived growth factor (PDGF), and has complete conservation of the eight cysteine residues found in both mature PDGF chains. The cysteine knot motif is a common feature of this domain. The homology is not reflected in function, however, since the cell types responsive to VEGF are distinct from those responsive to homo- and heterodimers of the PDGF chains. This protein is a glycosylated mitogen that acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. VEGF-A also has been shown to have effects on a number of other cell types (e.g. stimulation of monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells ). VEGF-A is also a vasodilator, it increases microvascular permeability, and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Antibody against VEGF-A (Bevacizumab or brand name Avastin) is approved for treatment of cancer by inhibiting angiogenesis. Ranibizumab, a Fab fragment of Avastin or so-called Lucentis is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This antibody is made from a humanized Fab fragment making it specific, efficient, and effective. Humanized Recombinant Anti-VEGF-A Fab fragment Antibody is useful for researchers interested in angiogenesis associated diseases such as cancer or wet AMD.

    ID gène

    7422

    NCBI Accession

    NP_001020537

    UniProt

    P15692

    Pathways

    Signalisation RTK, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling
Vous êtes ici:
Chat with us!